Pay in 4 interest-free payments of $7.05 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Personalized GLP-1 targets one pathway (GLP-1) that supports appetite regulation and metabolic health
Other significant considerations include: Injection site reactions (for subcutaneous formulations) Hypoglycaemia risk (particularly if used alongside other glucose-lowering medications) Pancreatitis (rare but serious) Gallbladder disease (including gallstones and cholecystitis) Dehydration leading to acute kidney injury (particularly with severe gastrointestinal side effects) Diabetic retinopathy complications (particularly noted with semaglutide in diabetes patients) Potential thyroid effects (medullary thyroid carcinoma risk in animal studies, though human relevance remains unclear) A Parkinson's-specific concern is that GLP-1 receptor agonists delay gastric emptying, which may further impair levodopa absorption and potentially worsen motor fluctuations or 'OFF' periods in patients on this medication
doi: 10.1016/j.molmet.2020.101102 23 AstrupACarraroRFinerNHarperAKunesovaMLeanMEJet al
Your medication was exposed to extreme temperature and you are unsure if it is still safe
Get help starting the conversation
Cell 172 , 393407 (2018)
US$ 20.86
US$ 21.53
US$ 23.36
US$ 20.20
US$ 23.85
